NS Partners Ltd Raises Stock Holdings in Masimo Co. (NASDAQ:MASI)

NS Partners Ltd raised its position in shares of Masimo Co. (NASDAQ:MASI) by 2.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,037 shares of the medical equipment provider’s stock after purchasing an additional 986 shares during the quarter. NS Partners Ltd owned 0.08% of Masimo worth $5,738,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MASI. NBC Securities Inc. boosted its position in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares during the last quarter. Lazard Asset Management LLC increased its stake in shares of Masimo by 5,730.0% in the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 573 shares during the period. Finally, HHM Wealth Advisors LLC raised its holdings in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Stock Performance

Shares of MASI stock opened at $163.50 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $173.90. The business’s 50 day moving average is $139.17 and its two-hundred day moving average is $127.02. The company has a market capitalization of $8.75 billion, a P/E ratio of 112.76 and a beta of 0.97.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 EPS. Analysts expect that Masimo Co. will post 4.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wells Fargo & Company upped their price target on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler lifted their price target on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective on the stock in a research report on Wednesday, November 6th. Finally, BTIG Research raised their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Masimo presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.